Puma Biotechnology's high P/E ratio is alarming due to its f...
Puma Biotechnology's high P/E ratio is alarming due to its falling earnings. Despite investor hopes for a business turnaround, analysts remain skeptical. The high P/E and anticipated future earnings drop make current prices seem unjustifiable unless conditions drastically improve.
Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 31% Price Boost Is Out Of Tune With Earnings
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment